304 related articles for article (PubMed ID: 25589335)
21. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
22. Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.
Lam S; Sung J; Cruz C; Castillo-Caro P; Ngo M; Garrido C; Kuruc J; Archin N; Rooney C; Margolis D; Bollard C
Mol Ther; 2015 Feb; 23(2):387-95. PubMed ID: 25366030
[TBL] [Abstract][Full Text] [Related]
23. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
24. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.
Shan L; Deng K; Shroff NS; Durand CM; Rabi SA; Yang HC; Zhang H; Margolick JB; Blankson JN; Siliciano RF
Immunity; 2012 Mar; 36(3):491-501. PubMed ID: 22406268
[TBL] [Abstract][Full Text] [Related]
25. Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.
Laird GM; Rosenbloom DI; Lai J; Siliciano RF; Siliciano JD
Methods Mol Biol; 2016; 1354():239-53. PubMed ID: 26714716
[TBL] [Abstract][Full Text] [Related]
26. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
[TBL] [Abstract][Full Text] [Related]
27. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
28. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
Spina CA; Anderson J; Archin NM; Bosque A; Chan J; Famiglietti M; Greene WC; Kashuba A; Lewin SR; Margolis DM; Mau M; Ruelas D; Saleh S; Shirakawa K; Siliciano RF; Singhania A; Soto PC; Terry VH; Verdin E; Woelk C; Wooden S; Xing S; Planelles V
PLoS Pathog; 2013; 9(12):e1003834. PubMed ID: 24385908
[TBL] [Abstract][Full Text] [Related]
29. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
Jones RB; Mueller S; O'Connor R; Rimpel K; Sloan DD; Karel D; Wong HC; Jeng EK; Thomas AS; Whitney JB; Lim SY; Kovacs C; Benko E; Karandish S; Huang SH; Buzon MJ; Lichterfeld M; Irrinki A; Murry JP; Tsai A; Yu H; Geleziunas R; Trocha A; Ostrowski MA; Irvine DJ; Walker BD
PLoS Pathog; 2016 Apr; 12(4):e1005545. PubMed ID: 27082643
[TBL] [Abstract][Full Text] [Related]
30. Broad activation of latent HIV-1 in vivo.
Barton K; Hiener B; Winckelmann A; Rasmussen TA; Shao W; Byth K; Lanfear R; Solomon A; McMahon J; Harrington S; Buzon M; Lichterfeld M; Denton PW; Olesen R; Østergaard L; Tolstrup M; Lewin SR; Søgaard OS; Palmer S
Nat Commun; 2016 Sep; 7():12731. PubMed ID: 27605062
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir.
Neidleman J; Luo X; Frouard J; Xie G; Hsiao F; Ma T; Morcilla V; Lee A; Telwatte S; Thomas R; Tamaki W; Wheeler B; Hoh R; Somsouk M; Vohra P; Milush J; James KS; Archin NM; Hunt PW; Deeks SG; Yukl SA; Palmer S; Greene WC; Roan NR
Elife; 2020 Sep; 9():. PubMed ID: 32990219
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic HIV-1 Nef blockade promotes CD8 T cell-mediated elimination of latently HIV-1-infected cells in vitro.
Mujib S; Saiyed A; Fadel S; Bozorgzad A; Aidarus N; Yue FY; Benko E; Kovacs C; Emert-Sedlak LA; Smithgall TE; Ostrowski MA
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878119
[TBL] [Abstract][Full Text] [Related]
33. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
[TBL] [Abstract][Full Text] [Related]
34. Killing of Latently HIV-Infected CD4 T Cells by Autologous CD8 T Cells Is Modulated by Nef.
Sevilya Z; Chorin E; Gal-Garber O; Zelinger E; Turner D; Avidor B; Berke G; Hassin D
Front Immunol; 2018; 9():2068. PubMed ID: 30254642
[TBL] [Abstract][Full Text] [Related]
35. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.
Ren Y; Huang SH; Patel S; Alberto WDC; Magat D; Ahimovic D; Macedo AB; Durga R; Chan D; Zale E; Mota TM; Truong R; Rohwetter T; McCann CD; Kovacs CM; Benko E; Wimpelberg A; Cannon C; Hardy WD; Bosque A; Bollard CM; Jones RB
J Clin Invest; 2020 May; 130(5):2542-2559. PubMed ID: 32027622
[TBL] [Abstract][Full Text] [Related]
36. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
[TBL] [Abstract][Full Text] [Related]
37. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.
Huang SH; Ren Y; Thomas AS; Chan D; Mueller S; Ward AR; Patel S; Bollard CM; Cruz CR; Karandish S; Truong R; Macedo AB; Bosque A; Kovacs C; Benko E; Piechocka-Trocha A; Wong H; Jeng E; Nixon DF; Ho YC; Siliciano RF; Walker BD; Jones RB
J Clin Invest; 2018 Feb; 128(2):876-889. PubMed ID: 29355843
[TBL] [Abstract][Full Text] [Related]
38. Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells.
Smith KN; Mailliard RB; Piazza PA; Fischer W; Korber BT; Fecek RJ; Ratner D; Gupta P; Mullins JI; Rinaldo CR
mBio; 2016 May; 7(3):. PubMed ID: 27247230
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1.
Doyon G; Sobolewski MD; Huber K; McMahon D; Mellors JW; Sluis-Cremer N
PLoS One; 2014; 9(1):e84964. PubMed ID: 24489654
[TBL] [Abstract][Full Text] [Related]
40. Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.
Ke R; Lewin SR; Elliott JH; Perelson AS
PLoS Pathog; 2015 Oct; 11(10):e1005237. PubMed ID: 26496627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
